GPR162 and Alzheimer disease: Concerning AD vs NAD in validation cohort, the AUC was 0.5875 for GABRD+-carrying pTau217 EVs, 0.5760 for GPR162+-carrying pTau217 EVs, 0.5329 for the distribution of GABRD+ carrying pTau217 EVs, and 0.5953 for the distribution of GPR162+ carrying pTau217 EVs.